Foundations Investment Advisors LLC Purchases 86 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Foundations Investment Advisors LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 11.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 849 shares of the pharmaceutical company’s stock after acquiring an additional 86 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $395,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of VRTX. Northwest Investment Counselors LLC acquired a new position in shares of Vertex Pharmaceuticals during the third quarter worth $25,000. Annapolis Financial Services LLC acquired a new position in Vertex Pharmaceuticals during the 1st quarter valued at about $27,000. GHP Investment Advisors Inc. acquired a new stake in Vertex Pharmaceuticals in the second quarter worth about $29,000. Stephens Consulting LLC purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter worth about $31,000. Finally, Founders Capital Management increased its holdings in shares of Vertex Pharmaceuticals by 50.0% during the second quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock valued at $35,000 after acquiring an additional 25 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ VRTX opened at $477.70 on Friday. The firm has a market cap of $123.27 billion, a price-to-earnings ratio of 31.00 and a beta of 0.40. The company’s 50-day simple moving average is $475.60 and its 200-day simple moving average is $461.36. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a 52-week low of $341.90 and a 52-week high of $510.64.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The firm had revenue of $2.65 billion during the quarter, compared to analyst estimates of $2.66 billion. During the same quarter in the previous year, the firm posted $3.53 earnings per share. The company’s quarterly revenue was up 6.1% on a year-over-year basis. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post -2.11 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on VRTX shares. StockNews.com downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 5th. UBS Group boosted their price objective on shares of Vertex Pharmaceuticals from $477.00 to $562.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Barclays cut Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $472.00 to $509.00 in a research report on Monday, August 5th. Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. Finally, Scotiabank initiated coverage on Vertex Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector perform” rating and a $480.00 target price for the company. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $492.92.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $508.00, for a total value of $2,689,860.00. Following the transaction, the director now owns 40,000 shares in the company, valued at approximately $20,320,000. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the sale, the director now owns 40,000 shares in the company, valued at approximately $20,320,000. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $476.75, for a total value of $1,086,990.00. Following the transaction, the chief marketing officer now owns 23,259 shares in the company, valued at approximately $11,088,728.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,005 shares of company stock worth $5,988,066. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.